ArticleMolecular imaging and biology2016
Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques.
Article in Molecular imaging and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review.European journal of nuclear medicine and molecular imaging · 2019Pooled it
- Detection of Atherosclerotic Inflammation byJournal of the American College of Cardiology · 2017 · on this mapTrial
- A Comprehensive Review of SSTR-Based Spect and Pet Imaging in Chronic Inflammatory and Immune-Mediated Diseases.Journal of clinical medicine · 2025Review
- Peptide Receptor Radionuclide Therapy UsingDiagnostics (Basel, Switzerland) · 2024Article
- Uncovering atherosclerotic cardiovascular disease by PET imaging.Nature reviews. Cardiology · 2024Review
- Somatostatin receptors in fibrotic myocardium.PloS one · 2024Article
- Recent Advances in Cardiovascular Diseases Research Using Animal Models and PET Radioisotope Tracers.International journal of molecular sciences · 2022Review
- Unravelling the role of macrophages in cardiovascular inflammation through imaging: a state-of-the-art review.European heart journal. Cardiovascular Imaging · 2022Review
- Potential novel imaging targets of inflammation in cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Review
- In vivo molecular and single cell imaging.BMB reports · 2022Review
- Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation.Scientific reports · 2022Article
- Imaging inflammation in atherosclerotic plaques, targeting SSTJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR).Journal of clinical medicine · 2021Review
- Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications.Molecules (Basel, Switzerland) · 2021Review
- Clinical Molecular Imaging for Atherosclerotic Plaque.Journal of imaging · 2021Review
- Imaging Inflammation in Patients and Animals: Focus on PET Imaging the Vulnerable Plaque.Cells · 2021Review
- Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.EJNMMI research · 2021Article
- Molecular Imaging of Inflammatory Disease.Biomedicines · 2021Review
- Beyond Vessel Diameters: Non-invasive Monitoring of Flow Patterns and Immune Cell Recruitment in Murine Abdominal Aortic Disorders by Multiparametric MRI.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRupture-prone atherosclerotic plaques are characterized by accumulation of macrophages, which have shown to express somatostatin type 2 receptors. We aimed to investigate whether somatostatin receptor-targeting positron emission tomography (PET) tracers, [(68)Ga]DOTANOC, [(18)F]FDR-NOC, and [(68)Ga]DOTATATE, can detect inflamed atherosclerotic plaques. PROCEDURES: Atherosclerotic IGF-II/LDLR(-/-)ApoB(100/100) mice were studied in vivo and ex vivo for tracer uptake into atherosclerotic plaques. Furthermore, [(68)Ga]DOTANOC and [(68)Ga]DOTATATE were compared in a head-to-head setting for in vivo PET/X-ray computed tomography (CT) imaging characteristics.
resultsEx vivo uptake of [(68)Ga]DOTANOC and [(68)Ga]DOTATATE in the aorta was higher in atherosclerotic mice compared to control C57Bl/6N mice, while the aortic uptake of [(18)F]FDR-NOC showed no genotype difference. Unlike [(18)F]FDR-NOC, [(68)Ga]DOTANOC and [(68)Ga]DOTATATE showed preferential binding to atherosclerotic plaques with plaque-to-wall ratio of 1.7 ± 0.3 and 2.1 ± 0.5, respectively. However, the aortic uptake and aorta-to-blood ratio of [(68)Ga]DOTANOC were higher compared to [(68)Ga]DOTATATE in in vivo PET/CT imaging.
conclusionOur results demonstrate superior applicability for [(68)Ga]DOTANOC and [(68)Ga]DOTATATE in the detection of atherosclerotic plaques compared to [(18)F]FDR-NOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.